Type 2 diabetes treatment is evolving fast—and the focus has shifted from managing blood sugar to preventing long-term complications early. In this episode of The Round Up, host A/Prof Elissa Hatherly speaks with Dr Luke Conway about the major paradigm shifts transforming diabetes care, from early diagnosis and aggressive therapy to the latest in medications and monitoring technologies.

Dr Conway explains how modern management now prioritises kidney and heart health, with SGLT2 inhibitors and GLP-1 agonists leading the way. He also explores the expanding role of continuous glucose monitoring (CGM), the potential of oral GLP-1s, and what’s on the horizon in diabetes medicine.

Whether you regularly manage patients with diabetes or just want to stay across the “tsunami” of new treatments on the way, this episode offers practical, up-to-date insights to support better outcomes in every practice.

Resources:

• Rosenstock, J, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. The New England Journal of Medicine 393 (2025) 1065-1076.

• FreeStyle Libre CGM

• Dexcom CGM

• Conway, L. ABC Checklist for Screening in T2D. Diabetes Management Journal May 2023 30-31.

• National Diabetes Services Scheme (NDSS)

• NDSS: Australian Type 2 Diabetes Glycaemic Management Algorithm